AIGEN Sciences Press Release

FLock.io and AIGEN Sciences Sign MoU to Deploy Privacy-Preserving AI in Drug Discovery

From left to right: Dr. Sunkyu Kim, Dr. Jaewoo Kang, Dr. Zehua Cheng, and Dr. Wei Dai — pictured at AIGEN’s Seoul headquarters during a pre-MoU meeting.

Seoul, South Korea & London, UK — 30 June 2025. FLock.io, the Web3-native platform for decentralized, privacy-preserving AI, and AIGEN Sciences, the award-winning AI-driven drug-discovery company, announced the signing of a Memorandum of Understanding (MoU) to integrate federated-learning technology with large-language-model-powered discovery tools, enabling pharmaceutical and clinical partners in South Korea to train AI models collaboratively without moving or exposing sensitive data.

Under the MoU the parties will connect FLock.io’s on-chain federated-learning infrastructure to AIGEN’s discovery engine, giving hospitals and research organizations a secure way to contribute real-world datasets while retaining full data control.

“This collaboration is an important milestone in making truly decentralized AI a reality for life-sciences,” said Jiahao Sun, Co-founder & CEO, FLock.io. “By pairing our blockchain-secured incentive layer with AIGEN’s proven drug-discovery stack, we can unlock high-value biomedical insights while upholding the strongest privacy standards.”

“AIGEN’s mission is to shorten the path from concept to clinic,” added Professor Jaewoo Kang, CEO, AIGEN Sciences. “FLock.io’s privacy-preserving technology lets us collaborate with hospitals and pharma companies on datasets that were previously off-limits. Together, we expect to deliver better medicines, faster.”

Dr. Zehua Cheng, Chief Scientist at FLock.io, and Dr. Sunkyu Kim, Director of AI Research at AIGEN, will co-lead the technical integration. Initial proof-of-concept studies are scheduled to begin in Q3 2025, with results to be shared at upcoming AI-for-healthcare conferences.

About FLock.io

FLock.io is a community-driven platform that combines federated learning and blockchain technology to create on-chain, decentralized AI models. Its incentive-aligned architecture allows data owners, compute providers, and AI engineers to collaborate securely without exposing raw data, ushering in a new era of privacy-preserving, democratized AI.

About AIGEN Sciences

AIGEN Sciences is a Seoul-based biotech company applying large-language-model and multi-omics technologies to accelerate small-molecule and biologics discovery. Backed by leading venture investors and founded by researchers from Korea University, AIGEN is advancing a diversified pipeline aimed at improving outcomes for patients worldwide.